News
LFCR
6.21
+2.31%
0.14
Weekly Report: what happened at LFCR last week (0715-0719)?
Weekly Report · 4d ago
Laughing Water Capital Q2 2024 Letter
Seeking Alpha · 07/19 11:32
Lifecore Biomedical, Inc. (NASDAQ:LFCR) hedge funds owners may be pleased with recent gains after 46% loss over the past year
Hedge funds own 36% of Lifecore Biomedical, Inc. (NASDAQ:LFCR) The company is owned by institutions and the top 8% of the company's shares. Hedge funds own the most shares in the company, with a 36% stake. Most of the stock is held by hedge funds, but there is some institutional ownership in the business. We also see that insiders own shares in lifecore biomedical. You can see the history of insider ownership of the firm and its share price.
Simply Wall St · 07/17 13:21
Enzo Biochem: Is This Time Finally Different?
Enzo Biochem's stock is trading near historic lows. Stock has potential for attractive returns with simplified Life Sciences division and strong CEO incentives. Company has $35m in cash after sale of Clinical Labs business to Labcorp Holdings. New CEO has been granted calls with a strike at $2 a share. Valuation potential of $2.00-3.22/share with $75-120m business value.
Seeking Alpha · 07/17 04:49
Weekly Report: what happened at LFCR last week (0708-0712)?
Weekly Report · 07/15 09:16
Lifecore Biomedical to Cut Nearly 9% of its Workforce, Book $1 Mln Costs
Dow Jones · 07/12 12:46
Lifecore Biomedical To Terminate 46 Full-Time Employees, About 9% Of Workforce; Estimates Termination Benefit Costs Of Approximately $1M
Benzinga · 07/12 12:08
LIFECORE BIOMEDICAL INC - ESTIMATES WILL INCUR TERMINATION BENEFIT COSTS OF ABOUT $1.0 MLN
Reuters · 07/12 12:04
LIFECORE BIOMEDICAL INC - TO TERMINATE 46 FULL-TIME EMPLOYEES OF REPRESENTING ABOUT 9% OF WORKFORCE
Reuters · 07/12 12:04
Cove Street Capital Q2 2024 Letter To Shareholders
Seeking Alpha · 07/11 17:20
Weekly Report: what happened at LFCR last week (0701-0705)?
Weekly Report · 07/08 09:17
NELSON OBUS-WYNNEFIELD REPORTING PERSONS AGREED TO CERTAIN CUSTOMARY STANDSTILL PROVISIONS WITH RESPECT TO ITS ACTIONS WITH REGARD TO LIFECORE
Reuters · 07/05 18:23
NELSON OBUS - BOARD OF LIFECORE BIOMEDICAL AGREED TO NOMINATE OBUS TO BOARD AS CLASS 1 DIRECTOR AT 2024 ANNUAL MEETING OF STOCKHOLDERS
Reuters · 07/05 18:23
NELSON OBUS - ON JUNE 28, LIFECORE BIOMEDICAL ENTERED INTO COOPERATION AGREEMENT WITH THE WYNNEFIELD REPORTING PERSONS
Reuters · 07/05 18:23
Lifecore Biomedical signs cooperation agreement with 22NW
M&A Lifecore Biomedical signs cooperation agreement with 22NW. The company added four new directors to the board effective immediately. 22NW will withdraw its notice of nominations of director candidates at the 2023 Annual Meeting. LifecORE Biomedical, Inc. (LFCR) stock.
Seeking Alpha · 07/01 13:13
Lifecore Biomedical Revamps Governance with Strategic Investor Agreements
TipRanks · 07/01 12:56
LIFECORE BIOMEDICAL: 22NW WILL WITHDRAW NOTICE OF NOMINATIONS OF DIRECTOR CANDIDATES AT 2023 ANNUAL MEETING
Reuters · 07/01 12:00
LIFECORE BIOMEDICAL INC - 22NW SIGNS STANDSTILL AND SUPPORT AGREEMENT
Reuters · 07/01 12:00
Press Release: Lifecore Biomedical Announces Cooperation Agreement with 22NW
Dow Jones · 07/01 12:00
Press Release: Lifecore Biomedical Announces -2-
Dow Jones · 07/01 12:00
More
Webull provides a variety of real-time LFCR stock news. You can receive the latest news about Lifecore Biomedical Inc through multiple platforms. This information may help you make smarter investment decisions.
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.